The firm said that adjuvant nivolumab had benefitted patients regardless of PD-L1 expression, and that the company will submit the data to regulatory agencies.
Data from ESMO positioned the competing checkpoint inhibitors as potential new standards of care in the first-line setting, but biomarker questions remain.
Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.
The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.
Once finalized, lung cancer patients in England can receive the drug for two years after they've received chemotherapy and if their tumors express PD-L1.
The statement is based on the IMpassion131 trial, in which the combination did not improve survival endpoints compared to paclitaxel in PD-L1-positive patients.
The study found immunomodulatory and angiogenesis gene expression signatures, mutational profiles, and HLA types could help predict how patients respond to therapy.
Researchers are homing in on the functional state of PD-L1 and PD-1 receptors in patients' tumors, rather than their expression levels, to predict checkpoint inhibitor response.
The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.
The serum-based proteomic test gauges a pre-treatment immune profile that has shown in retrospective studies to identify patients who are likely to respond well to anti-PD-1 therapy.
